1. ALLA AKTIER
  2. NYHETER
  3. SYNACT PHARMA

SynAct Pharma

Nyheter SynAct Pharma Nyheter alla bolag
Hej Visste du att du med vår premiumtjänst får fullständig historik i alla grafer, pressmeddelanden och andra notiser för dina favoritbolag direkt som DM i Discord samt en del andra godsaker? Du slipper dessutom störande annonser på sajten. Testa gratis i 14 dagar!

Synact Pharma large shareholder trading update

SynAct Pharma AB (publ) (”SynAct”) (Nasdaq Stockholm: SYNACT), a clinical-stage biotechnological company focused on treating inflammation through resolution, today announced, that the company has been informed by a large shareholder, that a trade of up to approximately 1 million shares was placed on the market Monday, May 25, due to an operational error between the bank and a private shareholder. The shareholder has informed Synact Pharma that the situation was identified and corrected, and that the order was cancelled by the bank shortly thereafter.

For further information, please contact:
Jeppe Øvlesen
CEO, SynAct Pharma AB
Phone: + 45 2844 7567
E-mail: investor.relations@synactpharma.com

About SynAct Pharma AB
SynAct Pharma AB (Nasdaq Stockholm: SYNACT) is a clinical stage biotechnology company focused on the resolution of inflammation through the selective activation of the melanocortin system. The company has a broad portfolio of oral and injectable selective melanocortin agonists aimed at inducing anti-inflammatory and inflammation resolution activity to help patients achieve immune balance and overcome their inflammation. For further information: https://synactpharma.com/.

Attachments
Synact Pharma large shareholder trading update

Datum 2026-05-26, kl 08:58
Källa MFN
Bifogade filer
Synact Pharma large shareholder trading update